Description
Approved accessible “rituximab-abbs injection”
TRUXIMA (rituximab-abbs) is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with:
• Non-Hodgkin’s Lymphoma (NHL)
o Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent.
o Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.
o Non-progressing (including stable disease), low-grade, CD20-positive,B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
How To access rituximab-abbs injection?
To access rituximab-abbs injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj)